Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma

Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma

Princeton, NJ – October 22, 2020 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that continued optional treatment with SGX301 (synthetic hypericin) across all lesions during the compassionate use, safety portion of the trial (Cycle 3), for a total of 6 months in the study, continued to significantly improve responses and remained safe and well-tolerated in its FLASH (Fluorescent Light Activated Synthetic Hypericin) study.  This data reinforces the positive SGX301 primary endpoint treatment response demonstrated in Cycle 1.

Please refer to the Soligenix press release for full information http://ir.soligenix.com/2020-10-22-Soligenix-Announces-Phase-3-FLASH-Study-Continues-to-Demonstrate-Positive-Benefits-in-Patients-with-Cutaneous-T-Cell-Lymphoma.

  • Nearly half of all patients in Phase 3 trial continue to see sustained and statistically significant improvement in their response rates when treated with SGX301 through 18 weeks (Cycle 3), reinforcing positive SGX301 primary endpoint treatment response
  • SGX301 remains safe and well tolerated with no systemic exposure through 6 months including the optional, final cycle of the trial (Cycle 3)
  • SGX301 demonstrates statistically significant response in both patch and plaque lesions through 12 weeks of treatment (Cycle 2), highlighting the unique benefits of deeper skin penetration  

Company Contact:

Jonathan Guarino, CPA, CGMA

Senior Vice President and Chief Financial Officer

(609) 538-8200 | www.soligenix.com